secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001576280-23-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health prelim FY22 revenue $447-450M, up 20%; test volumes up >40% YoY
-------------------------------------------------------------------------------

- Preliminary FY22 revenue $447M-$450M, up 20% YoY; Q4 revenue $124M-$127M, up 15-17%.
- FY22 clinical test volumes 124,800 (+42% YoY); biopharma tests 26,000 (+40% YoY).
- Q4 clinical tests 36,000 (+41% YoY); biopharma tests 8,200 (+24% YoY).
- Cash, equivalents and marketable debt securities $1.0B as of Dec 31, 2022.
- Positive ECLIPSE trial readout for Shield blood-based colorectal cancer test; expanding to lung cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/0001576280-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000005/gh-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001576280-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer